Order Drugs Now

TEL: 1 866 893 0369
FAX: 1 866 402 4033

Medical News

Subscribe to Newsletter

To get info on the latest products, specials and pharmacy news, please enter your e-mail address:


August 13th, 2009
Top-Line Results From Zelrix Phase III, Clinical Trials

Pharmaceutical company NuPathe Inc., who specializes in the generation of revolutionary products to treat neurological and psychiatric diseases, publicizes top-line results from the Phase III Zelrix clinical trial. Zelrix is a clinically developed transdermal patch used for the treatment of acute migraines. The double-blind, placebo-controlled trial occurred in a multi-center, nonspecific, parallel group. The effectiveness and bearability of the migraine treatment was contrasted against placebo treatments in 530 adults.

Jane Hollingsworth, chief executive officer of NuPathe explains “Zelrix was designed to overcome key barriers to successful treatment of migraine; treatment-altering nausea, treatment-limiting side effects and inconsistent drug absorption.” Zelrix’s migraine patch utilizes the company’s exclusive iontophoretic transdermal technology, SmartRelief with a common prescribed treatment for migraines, sumatriptan.

Two hours post application, patients who administered the Zelrix patch showed notable advancements on all five of the key effectiveness end points, compared with those patients who administered the placebo patch. The endpoints include: pain free (pain symptom score = 0), pain relief, nausea free, photophobia free and phonophobia free.

Zelrix caused low triptan-specific side effects. The most common side effects were mild and transient itching, pain and tingling at the application site.


Search for Medication or Types of Conditions



: 0
Total: $0.00

view my cart check out credit cards

Find out how much you can save now!

download order form


Medicine Shoppe Pharmacy
148 #9 31205 Maclure Road
Abbotsford BC, Canada

Ph: 1-866-893-0369
Fax: 1-800-878-7930

Licence J30
Manager: S. Maan


TEL: 1 (866) 893-0369
FAX: 1 (800) 878-7930